[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$foJLTVqQnxUBTATO5wo0cx9OP1oReTdpBC5ISjDS6nxA":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":8,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":34,"phaseBuckets":84,"rows":91},"Institute of Cancer Research, United Kingdom",[4],111,false,39,19,105762,55,[13,16,19,22,25,28,30,32],{"name":14,"count":15},"Breast Cancer",20,{"name":17,"count":18},"Prostate Cancer",18,{"name":20,"count":21},"Cancer",12,{"name":23,"count":24},"Bladder Cancer",5,{"name":26,"count":27},"Malignant Primary Gliomas",3,{"name":29,"count":27},"Glioblastoma Multiforme (GBM)",{"name":31,"count":27},"Adenocarcinoma of the Prostate",{"name":33,"count":27},"Triple Negative Breast Cancer",[35,40,45,50,54,59,64,69,74,79],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT03158922","The BARCODE 1 Pilot Study","2018-04-14","Genetic SNP profiling",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT03875820","Phase I Trial of Defactinib and VS-6766.","2023-04-30","VS-6766",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT02338310","Trial of Perioperative Endocrine Therapy - Individualising Care","2024-04","Aromatase Inhibitors",{"nctId":51,"briefTitle":52,"date":53,"intervention":39},"NCT03857477","The BARCODE 1 Study (Full Study): The Use of Genetic Profiling to Guide Prostate Cancer Targeted Screening.","2024-04-01",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT03673787","A Trial of Ipatasertib in Combination With Atezolizumab","2026-03","ipatasertib",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT06632236","5G-EMERALD: Amivantamab in Malignant Brain Tumours","2026-03-05","Amivantamab",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT05082259","ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab","2026-03-16","ASTX660",{"nctId":70,"briefTitle":71,"date":72,"intervention":73},"NCT06126731","Combination Study of Antibiotics With Enzalutamide (PROMIZE)","2026-06-30","Enzalutamide 40mg",{"nctId":75,"briefTitle":76,"date":77,"intervention":78},"NCT04065269","ATr Inhibitor in Combination With Olaparib\u002FDurvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss","2026-08","Ceralasertib",{"nctId":80,"briefTitle":81,"date":82,"intervention":83},"NCT03740893","PHOENIX DDR\u002FAnti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer","2026-12","AZD6738",[85,86,87,88,89,90],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[92,121,139,168,186,204,225,281,340,362,391,428,450,482,507,525,543,561,579,597,623,641,665,683,701,724,742,797,817,835,864,882,900,918,936,954,972,998,1023,1049,1111,1147,1173,1205,1227,1249,1271,1300,1322,1348,1366,1391,1409,1427,1445,1463,1481,1499,1517,1535,1553,1577,1602,1630,1658,1676,1701,1719,1744,1769,1787,1813,1839,1865,1883,1901,1927,1945,1963,1987,2012,2049,2077,2101,2119,2145],{"intervention":93,"totalTrials":94,"cells":95},"Abemaciclib",1,{"EARLY_PHASE1":96,"PHASE1":99,"PHASE2":101,"PHASE3":103,"PHASE4":117,"NA":119},{"trials":97,"activeCount":98},[],0,{"trials":100,"activeCount":98},[],{"trials":102,"activeCount":98},[],{"trials":104,"activeCount":94,"soonestReadout":110},[105],{"nctId":106,"briefTitle":107,"status":108,"phases":109,"primaryCompletion":110,"completion":110,"start":111,"enrollment":112,"conditions":113,"interventions":115},"NCT04584853","PreOperative Endocrine Therapy for Individualised Care With Abemaciclib","ACTIVE_NOT_RECRUITING",[88],"2030-10","2020-12-23",123,[114],"Breast Cancer Female",[93,116],"Endocrine therapy",{"trials":118,"activeCount":98},[],{"trials":120,"activeCount":98},[],{"intervention":116,"totalTrials":94,"cells":122},{"EARLY_PHASE1":123,"PHASE1":125,"PHASE2":127,"PHASE3":129,"PHASE4":135,"NA":137},{"trials":124,"activeCount":98},[],{"trials":126,"activeCount":98},[],{"trials":128,"activeCount":98},[],{"trials":130,"activeCount":94,"soonestReadout":110},[131],{"nctId":106,"briefTitle":107,"status":108,"phases":132,"primaryCompletion":110,"completion":110,"start":111,"enrollment":112,"conditions":133,"interventions":134},[88],[114],[93,116],{"trials":136,"activeCount":98},[],{"trials":138,"activeCount":98},[],{"intervention":140,"totalTrials":94,"cells":141},"Paclitaxel",{"EARLY_PHASE1":142,"PHASE1":144,"PHASE2":146,"PHASE3":148,"PHASE4":164,"NA":166},{"trials":143,"activeCount":98},[],{"trials":145,"activeCount":98},[],{"trials":147,"activeCount":98},[],{"trials":149,"activeCount":94,"soonestReadout":155},[150],{"nctId":151,"briefTitle":152,"status":153,"phases":154,"primaryCompletion":155,"completion":156,"start":157,"enrollment":158,"conditions":159,"interventions":161},"NCT02305654","International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)","RECRUITING",[88],"2027-05-31","2027-11-30","2017-05-12",200,[160],"Squamous Cell Carcinoma of the Penis, Usual Type",[140,162,163],"Ifosfamide","Cisplatin",{"trials":165,"activeCount":98},[],{"trials":167,"activeCount":98},[],{"intervention":162,"totalTrials":94,"cells":169},{"EARLY_PHASE1":170,"PHASE1":172,"PHASE2":174,"PHASE3":176,"PHASE4":182,"NA":184},{"trials":171,"activeCount":98},[],{"trials":173,"activeCount":98},[],{"trials":175,"activeCount":98},[],{"trials":177,"activeCount":94,"soonestReadout":155},[178],{"nctId":151,"briefTitle":152,"status":153,"phases":179,"primaryCompletion":155,"completion":156,"start":157,"enrollment":158,"conditions":180,"interventions":181},[88],[160],[140,162,163],{"trials":183,"activeCount":98},[],{"trials":185,"activeCount":98},[],{"intervention":163,"totalTrials":94,"cells":187},{"EARLY_PHASE1":188,"PHASE1":190,"PHASE2":192,"PHASE3":194,"PHASE4":200,"NA":202},{"trials":189,"activeCount":98},[],{"trials":191,"activeCount":98},[],{"trials":193,"activeCount":98},[],{"trials":195,"activeCount":94,"soonestReadout":155},[196],{"nctId":151,"briefTitle":152,"status":153,"phases":197,"primaryCompletion":155,"completion":156,"start":157,"enrollment":158,"conditions":198,"interventions":199},[88],[160],[140,162,163],{"trials":201,"activeCount":98},[],{"trials":203,"activeCount":98},[],{"intervention":49,"totalTrials":94,"cells":205},{"EARLY_PHASE1":206,"PHASE1":208,"PHASE2":210,"PHASE3":212,"PHASE4":221,"NA":223},{"trials":207,"activeCount":98},[],{"trials":209,"activeCount":98},[],{"trials":211,"activeCount":98},[],{"trials":213,"activeCount":94,"soonestReadout":48},[214],{"nctId":46,"briefTitle":47,"status":108,"phases":215,"primaryCompletion":48,"completion":216,"start":217,"enrollment":218,"conditions":219,"interventions":220},[88],"2034-04","2008-09",4486,[14],[49],{"trials":222,"activeCount":98},[],{"trials":224,"activeCount":98},[],{"intervention":226,"totalTrials":27,"cells":227},"Temozolomide",{"EARLY_PHASE1":228,"PHASE1":230,"PHASE2":232,"PHASE3":260,"PHASE4":277,"NA":279},{"trials":229,"activeCount":98},[],{"trials":231,"activeCount":98},[],{"trials":233,"activeCount":259,"soonestReadout":238},[234,245],{"nctId":235,"briefTitle":236,"status":153,"phases":237,"primaryCompletion":238,"completion":239,"start":240,"enrollment":241,"conditions":242,"interventions":243},"NCT07391215","5G-PEARL: Paxalisib in Malignant Brain Tumours",[86,87],"2029-01-19","2029-06-30","2026-01-19",64,[26,29],[244,226],"Paxalisib",{"nctId":246,"briefTitle":247,"status":153,"phases":248,"primaryCompletion":249,"completion":250,"start":251,"enrollment":252,"conditions":253,"interventions":256},"NCT06630260","5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours",[86,87],"2029-09-30","2030-09-30","2024-11-15",182,[29,254,255,26],"Glioblastoma Multiform (Grade IV Astrocytoma)","Diffuse Hemispheric Glioma, H3 G34-Mutant",[257,258,226],"Avutometinib","Defactinib",2,{"trials":261,"activeCount":98},[262],{"nctId":263,"briefTitle":264,"status":265,"phases":266,"completion":267,"start":268,"enrollment":269,"conditions":270,"interventions":272},"NCT00052455","Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma","COMPLETED",[88],"2010-09","2002-10",500,[271],"Brain and Central Nervous System Tumors",[273,274,275,276],"lomustine","procarbazine hydrochloride","temozolomide","vincristine sulfate",{"trials":278,"activeCount":98},[],{"trials":280,"activeCount":98},[],{"intervention":282,"totalTrials":283,"cells":284},"Olaparib",4,{"EARLY_PHASE1":285,"PHASE1":287,"PHASE2":289,"PHASE3":334,"PHASE4":336,"NA":338},{"trials":286,"activeCount":98},[],{"trials":288,"activeCount":98},[],{"trials":290,"activeCount":259,"soonestReadout":77},[291,302,317,324],{"nctId":80,"briefTitle":81,"status":153,"phases":292,"primaryCompletion":82,"completion":293,"start":294,"enrollment":295,"conditions":296,"interventions":300},[87],"2029-06","2019-10-15",119,[297,298,299],"Breast Neoplasm","Triple Negative Breast Cancer (TNBC)","HRD",[83,282,301],"Durvalumab",{"nctId":303,"briefTitle":304,"status":305,"phases":306,"primaryCompletion":307,"completion":308,"start":309,"enrollment":310,"conditions":311,"interventions":313},"NCT03182634","The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) Trial","UNKNOWN",[87],"2022-11","2023-11","2016-12-15",1150,[312],"Advanced Breast Cancer",[314,315,316,282,83],"Fulvestrant","Neratinib","AZD5363",{"nctId":75,"briefTitle":76,"status":108,"phases":318,"primaryCompletion":77,"completion":77,"start":319,"enrollment":320,"conditions":321,"interventions":323},[87],"2019-11-27",174,[322],"Gynaecological Cancers",[78,282,301],{"nctId":325,"briefTitle":326,"status":305,"phases":327,"primaryCompletion":328,"completion":329,"start":330,"enrollment":331,"conditions":332,"interventions":333},"NCT01682772","TOPARP: A Phase II Trial of Olaparib in Patients With Advanced Castration Resistant Prostate Cancer",[87],"2019-03","2020-02","2012-07",148,[31],[282],{"trials":335,"activeCount":98},[],{"trials":337,"activeCount":98},[],{"trials":339,"activeCount":98},[],{"intervention":301,"totalTrials":259,"cells":341},{"EARLY_PHASE1":342,"PHASE1":344,"PHASE2":346,"PHASE3":356,"PHASE4":358,"NA":360},{"trials":343,"activeCount":98},[],{"trials":345,"activeCount":98},[],{"trials":347,"activeCount":259,"soonestReadout":77},[348,352],{"nctId":80,"briefTitle":81,"status":153,"phases":349,"primaryCompletion":82,"completion":293,"start":294,"enrollment":295,"conditions":350,"interventions":351},[87],[297,298,299],[83,282,301],{"nctId":75,"briefTitle":76,"status":108,"phases":353,"primaryCompletion":77,"completion":77,"start":319,"enrollment":320,"conditions":354,"interventions":355},[87],[322],[78,282,301],{"trials":357,"activeCount":98},[],{"trials":359,"activeCount":98},[],{"trials":361,"activeCount":98},[],{"intervention":258,"totalTrials":259,"cells":363},{"EARLY_PHASE1":364,"PHASE1":366,"PHASE2":379,"PHASE3":385,"PHASE4":387,"NA":389},{"trials":365,"activeCount":98},[],{"trials":367,"activeCount":94,"soonestReadout":43},[368],{"nctId":41,"briefTitle":42,"status":108,"phases":369,"primaryCompletion":43,"completion":370,"start":371,"enrollment":372,"conditions":373,"interventions":378},[86],"2026-10-31","2017-12-12",87,[374,375,376,377],"NSCLC","Low Grade Serous Ovarian Cancer","Endometrioid Carcinoma","Pancreatic Cancer",[44,258],{"trials":380,"activeCount":94,"soonestReadout":249},[381],{"nctId":246,"briefTitle":247,"status":153,"phases":382,"primaryCompletion":249,"completion":250,"start":251,"enrollment":252,"conditions":383,"interventions":384},[86,87],[29,254,255,26],[257,258,226],{"trials":386,"activeCount":98},[],{"trials":388,"activeCount":98},[],{"trials":390,"activeCount":98},[],{"intervention":392,"totalTrials":259,"cells":393},"Carboplatin",{"EARLY_PHASE1":394,"PHASE1":396,"PHASE2":398,"PHASE3":411,"PHASE4":424,"NA":426},{"trials":395,"activeCount":98},[],{"trials":397,"activeCount":98},[],{"trials":399,"activeCount":94,"soonestReadout":404},[400],{"nctId":401,"briefTitle":402,"status":108,"phases":403,"primaryCompletion":404,"completion":405,"start":406,"enrollment":407,"conditions":408,"interventions":410},"NCT02955082","The BARCODE 2 Study - The Use of Genetic Profiling to Guide Prostate Cancer Treatment",[87],"2026-12-31","2028-12-31","2017-05-25",305,[409],"Hormone Refractory Prostate Cancer",[392],{"trials":412,"activeCount":98},[413],{"nctId":414,"briefTitle":415,"status":305,"phases":416,"primaryCompletion":417,"completion":418,"start":419,"enrollment":420,"conditions":421,"interventions":422},"NCT00532727","Triple Negative Breast Cancer Trial",[88],"2016-03","2020-03","2008-01",400,[14],[392,423],"Docetaxel",{"trials":425,"activeCount":98},[],{"trials":427,"activeCount":98},[],{"intervention":83,"totalTrials":259,"cells":429},{"EARLY_PHASE1":430,"PHASE1":432,"PHASE2":434,"PHASE3":444,"PHASE4":446,"NA":448},{"trials":431,"activeCount":98},[],{"trials":433,"activeCount":98},[],{"trials":435,"activeCount":94,"soonestReadout":82},[436,440],{"nctId":80,"briefTitle":81,"status":153,"phases":437,"primaryCompletion":82,"completion":293,"start":294,"enrollment":295,"conditions":438,"interventions":439},[87],[297,298,299],[83,282,301],{"nctId":303,"briefTitle":304,"status":305,"phases":441,"primaryCompletion":307,"completion":308,"start":309,"enrollment":310,"conditions":442,"interventions":443},[87],[312],[314,315,316,282,83],{"trials":445,"activeCount":98},[],{"trials":447,"activeCount":98},[],{"trials":449,"activeCount":98},[],{"intervention":451,"totalTrials":259,"cells":452},"Hydrogen Peroxide",{"EARLY_PHASE1":453,"PHASE1":455,"PHASE2":457,"PHASE3":476,"PHASE4":478,"NA":480},{"trials":454,"activeCount":98},[],{"trials":456,"activeCount":98},[],{"trials":458,"activeCount":94,"soonestReadout":463},[459,468],{"nctId":460,"briefTitle":461,"status":153,"phases":462,"primaryCompletion":463,"completion":463,"start":464,"enrollment":465,"conditions":466,"interventions":467},"NCT03946202","KORTUC Phase II - Intra-tumoural Radiation Sensitizer in Patients With Locally Advanced\u002FRecurrent Breast Cancer",[87],"2028-06-30","2020-06-16",184,[14],[451],{"nctId":469,"briefTitle":470,"status":265,"phases":471,"primaryCompletion":472,"completion":472,"start":473,"enrollment":21,"conditions":474,"interventions":475},"NCT02757651","KORTUC: Intra-tumoural Hydrogen Peroxide as a Radiation Sensitizer in Patients With Locally Advanced\u002FRecurrent Breast Cancer in Terms of Toxicity and Tumour Response",[86,87],"2020-11-12","2017-01-19",[14],[451],{"trials":477,"activeCount":98},[],{"trials":479,"activeCount":98},[],{"trials":481,"activeCount":98},[],{"intervention":73,"totalTrials":94,"cells":483},{"EARLY_PHASE1":484,"PHASE1":486,"PHASE2":488,"PHASE3":501,"PHASE4":503,"NA":505},{"trials":485,"activeCount":98},[],{"trials":487,"activeCount":98},[],{"trials":489,"activeCount":94,"soonestReadout":72},[490],{"nctId":70,"briefTitle":71,"status":153,"phases":491,"primaryCompletion":72,"completion":492,"start":493,"enrollment":8,"conditions":494,"interventions":496},[86,87],"2027-06-30","2023-11-02",[495],"Metastatic Castration-Resistant Prostate Cancer (mCRPC)",[73,497,498,499,500],"Amoxicillin 500mg","Metronidazole 400mg","Vancomycin 125mg","Ciprofloxacin 500g",{"trials":502,"activeCount":98},[],{"trials":504,"activeCount":98},[],{"trials":506,"activeCount":98},[],{"intervention":497,"totalTrials":94,"cells":508},{"EARLY_PHASE1":509,"PHASE1":511,"PHASE2":513,"PHASE3":519,"PHASE4":521,"NA":523},{"trials":510,"activeCount":98},[],{"trials":512,"activeCount":98},[],{"trials":514,"activeCount":94,"soonestReadout":72},[515],{"nctId":70,"briefTitle":71,"status":153,"phases":516,"primaryCompletion":72,"completion":492,"start":493,"enrollment":8,"conditions":517,"interventions":518},[86,87],[495],[73,497,498,499,500],{"trials":520,"activeCount":98},[],{"trials":522,"activeCount":98},[],{"trials":524,"activeCount":98},[],{"intervention":498,"totalTrials":94,"cells":526},{"EARLY_PHASE1":527,"PHASE1":529,"PHASE2":531,"PHASE3":537,"PHASE4":539,"NA":541},{"trials":528,"activeCount":98},[],{"trials":530,"activeCount":98},[],{"trials":532,"activeCount":94,"soonestReadout":72},[533],{"nctId":70,"briefTitle":71,"status":153,"phases":534,"primaryCompletion":72,"completion":492,"start":493,"enrollment":8,"conditions":535,"interventions":536},[86,87],[495],[73,497,498,499,500],{"trials":538,"activeCount":98},[],{"trials":540,"activeCount":98},[],{"trials":542,"activeCount":98},[],{"intervention":499,"totalTrials":94,"cells":544},{"EARLY_PHASE1":545,"PHASE1":547,"PHASE2":549,"PHASE3":555,"PHASE4":557,"NA":559},{"trials":546,"activeCount":98},[],{"trials":548,"activeCount":98},[],{"trials":550,"activeCount":94,"soonestReadout":72},[551],{"nctId":70,"briefTitle":71,"status":153,"phases":552,"primaryCompletion":72,"completion":492,"start":493,"enrollment":8,"conditions":553,"interventions":554},[86,87],[495],[73,497,498,499,500],{"trials":556,"activeCount":98},[],{"trials":558,"activeCount":98},[],{"trials":560,"activeCount":98},[],{"intervention":500,"totalTrials":94,"cells":562},{"EARLY_PHASE1":563,"PHASE1":565,"PHASE2":567,"PHASE3":573,"PHASE4":575,"NA":577},{"trials":564,"activeCount":98},[],{"trials":566,"activeCount":98},[],{"trials":568,"activeCount":94,"soonestReadout":72},[569],{"nctId":70,"briefTitle":71,"status":153,"phases":570,"primaryCompletion":72,"completion":492,"start":493,"enrollment":8,"conditions":571,"interventions":572},[86,87],[495],[73,497,498,499,500],{"trials":574,"activeCount":98},[],{"trials":576,"activeCount":98},[],{"trials":578,"activeCount":98},[],{"intervention":78,"totalTrials":94,"cells":580},{"EARLY_PHASE1":581,"PHASE1":583,"PHASE2":585,"PHASE3":591,"PHASE4":593,"NA":595},{"trials":582,"activeCount":98},[],{"trials":584,"activeCount":98},[],{"trials":586,"activeCount":94,"soonestReadout":77},[587],{"nctId":75,"briefTitle":76,"status":108,"phases":588,"primaryCompletion":77,"completion":77,"start":319,"enrollment":320,"conditions":589,"interventions":590},[87],[322],[78,282,301],{"trials":592,"activeCount":98},[],{"trials":594,"activeCount":98},[],{"trials":596,"activeCount":98},[],{"intervention":598,"totalTrials":94,"cells":599},"SX-682",{"EARLY_PHASE1":600,"PHASE1":602,"PHASE2":604,"PHASE3":617,"PHASE4":619,"NA":621},{"trials":601,"activeCount":98},[],{"trials":603,"activeCount":98},[],{"trials":605,"activeCount":94,"soonestReadout":610},[606],{"nctId":607,"briefTitle":608,"status":153,"phases":609,"primaryCompletion":610,"completion":610,"start":611,"enrollment":612,"conditions":613,"interventions":615},"NCT07002320","Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer",[86,87],"2029-10","2025-04-28",78,[614],"Metastatic Castrate-Resistant Prostate Cancer (mCRPC)",[598,616],"Apalutamide",{"trials":618,"activeCount":98},[],{"trials":620,"activeCount":98},[],{"trials":622,"activeCount":98},[],{"intervention":616,"totalTrials":94,"cells":624},{"EARLY_PHASE1":625,"PHASE1":627,"PHASE2":629,"PHASE3":635,"PHASE4":637,"NA":639},{"trials":626,"activeCount":98},[],{"trials":628,"activeCount":98},[],{"trials":630,"activeCount":94,"soonestReadout":610},[631],{"nctId":607,"briefTitle":608,"status":153,"phases":632,"primaryCompletion":610,"completion":610,"start":611,"enrollment":612,"conditions":633,"interventions":634},[86,87],[614],[598,616],{"trials":636,"activeCount":98},[],{"trials":638,"activeCount":98},[],{"trials":640,"activeCount":98},[],{"intervention":642,"totalTrials":94,"cells":643},"Niraparib oral",{"EARLY_PHASE1":644,"PHASE1":646,"PHASE2":648,"PHASE3":659,"PHASE4":661,"NA":663},{"trials":645,"activeCount":98},[],{"trials":647,"activeCount":98},[],{"trials":649,"activeCount":94,"soonestReadout":492},[650],{"nctId":651,"briefTitle":652,"status":153,"phases":653,"primaryCompletion":492,"completion":492,"start":654,"enrollment":655,"conditions":656,"interventions":658},"NCT05990192","SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy",[87],"2024-06-20",42,[657],"Ovarian Cancer Recurrent",[642],{"trials":660,"activeCount":98},[],{"trials":662,"activeCount":98},[],{"trials":664,"activeCount":98},[],{"intervention":244,"totalTrials":94,"cells":666},{"EARLY_PHASE1":667,"PHASE1":669,"PHASE2":671,"PHASE3":677,"PHASE4":679,"NA":681},{"trials":668,"activeCount":98},[],{"trials":670,"activeCount":98},[],{"trials":672,"activeCount":94,"soonestReadout":238},[673],{"nctId":235,"briefTitle":236,"status":153,"phases":674,"primaryCompletion":238,"completion":239,"start":240,"enrollment":241,"conditions":675,"interventions":676},[86,87],[26,29],[244,226],{"trials":678,"activeCount":98},[],{"trials":680,"activeCount":98},[],{"trials":682,"activeCount":98},[],{"intervention":257,"totalTrials":94,"cells":684},{"EARLY_PHASE1":685,"PHASE1":687,"PHASE2":689,"PHASE3":695,"PHASE4":697,"NA":699},{"trials":686,"activeCount":98},[],{"trials":688,"activeCount":98},[],{"trials":690,"activeCount":94,"soonestReadout":249},[691],{"nctId":246,"briefTitle":247,"status":153,"phases":692,"primaryCompletion":249,"completion":250,"start":251,"enrollment":252,"conditions":693,"interventions":694},[86,87],[29,254,255,26],[257,258,226],{"trials":696,"activeCount":98},[],{"trials":698,"activeCount":98},[],{"trials":700,"activeCount":98},[],{"intervention":58,"totalTrials":94,"cells":702},{"EARLY_PHASE1":703,"PHASE1":705,"PHASE2":707,"PHASE3":718,"PHASE4":720,"NA":722},{"trials":704,"activeCount":98},[],{"trials":706,"activeCount":98},[],{"trials":708,"activeCount":94,"soonestReadout":57},[709],{"nctId":55,"briefTitle":56,"status":108,"phases":710,"primaryCompletion":57,"completion":57,"start":711,"enrollment":372,"conditions":712,"interventions":716},[86,87],"2018-08-13",[713,714,715],"Solid Tumor","Glioblastoma Multiforme","Prostate Cancer Metastatic",[58,717],"Atezolizumab",{"trials":719,"activeCount":98},[],{"trials":721,"activeCount":98},[],{"trials":723,"activeCount":98},[],{"intervention":717,"totalTrials":94,"cells":725},{"EARLY_PHASE1":726,"PHASE1":728,"PHASE2":730,"PHASE3":736,"PHASE4":738,"NA":740},{"trials":727,"activeCount":98},[],{"trials":729,"activeCount":98},[],{"trials":731,"activeCount":94,"soonestReadout":57},[732],{"nctId":55,"briefTitle":56,"status":108,"phases":733,"primaryCompletion":57,"completion":57,"start":711,"enrollment":372,"conditions":734,"interventions":735},[86,87],[713,714,715],[58,717],{"trials":737,"activeCount":98},[],{"trials":739,"activeCount":98},[],{"trials":741,"activeCount":98},[],{"intervention":743,"totalTrials":283,"cells":744},"Pembrolizumab",{"EARLY_PHASE1":745,"PHASE1":747,"PHASE2":768,"PHASE3":791,"PHASE4":793,"NA":795},{"trials":746,"activeCount":98},[],{"trials":748,"activeCount":259,"soonestReadout":67},[749,761],{"nctId":750,"briefTitle":751,"status":108,"phases":752,"primaryCompletion":753,"completion":754,"start":755,"enrollment":9,"conditions":756,"interventions":759},"NCT05782361","POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC",[86],"2028-03-08","2029-01-09","2023-05-03",[757,758],"Advanced Cancer","Non Small Cell Lung Cancer",[760,743],"Tepotinib",{"nctId":65,"briefTitle":66,"status":153,"phases":762,"primaryCompletion":67,"completion":67,"start":763,"enrollment":764,"conditions":765,"interventions":767},[86],"2022-03-02",61,[757,766,33],"Cervical Cancer",[68,743],{"trials":769,"activeCount":98},[770,780],{"nctId":771,"briefTitle":772,"status":305,"phases":773,"primaryCompletion":774,"completion":775,"start":776,"enrollment":777,"conditions":778,"interventions":779},"NCT03145961","A Trial Using ctDNA Blood Tests to Detect Cancer Cells After Standard Treatment to Trigger Additional Treatment in Early Stage Triple Negative Breast Cancer Patients",[87],"2021-09-30","2024-03-31","2017-12-21",208,[33],[743],{"nctId":781,"briefTitle":782,"status":305,"phases":783,"primaryCompletion":784,"completion":785,"start":786,"enrollment":787,"conditions":788,"interventions":790},"NCT03506997","Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer",[87],"2023-09-01","2025-09-01","2018-11-27",100,[789],"Castration-resistant Prostate Cancer",[743],{"trials":792,"activeCount":98},[],{"trials":794,"activeCount":98},[],{"trials":796,"activeCount":98},[],{"intervention":63,"totalTrials":94,"cells":798},{"EARLY_PHASE1":799,"PHASE1":801,"PHASE2":809,"PHASE3":811,"PHASE4":813,"NA":815},{"trials":800,"activeCount":98},[],{"trials":802,"activeCount":94,"soonestReadout":62},[803],{"nctId":60,"briefTitle":61,"status":153,"phases":804,"primaryCompletion":62,"completion":805,"start":806,"enrollment":21,"conditions":807,"interventions":808},[86],"2027-03-05","2024-10-09",[26,254,255,29],[63],{"trials":810,"activeCount":98},[],{"trials":812,"activeCount":98},[],{"trials":814,"activeCount":98},[],{"trials":816,"activeCount":98},[],{"intervention":44,"totalTrials":94,"cells":818},{"EARLY_PHASE1":819,"PHASE1":821,"PHASE2":827,"PHASE3":829,"PHASE4":831,"NA":833},{"trials":820,"activeCount":98},[],{"trials":822,"activeCount":94,"soonestReadout":43},[823],{"nctId":41,"briefTitle":42,"status":108,"phases":824,"primaryCompletion":43,"completion":370,"start":371,"enrollment":372,"conditions":825,"interventions":826},[86],[374,375,376,377],[44,258],{"trials":828,"activeCount":98},[],{"trials":830,"activeCount":98},[],{"trials":832,"activeCount":98},[],{"trials":834,"activeCount":98},[],{"intervention":836,"totalTrials":94,"cells":837},"Dose Level 2",{"EARLY_PHASE1":838,"PHASE1":840,"PHASE2":856,"PHASE3":858,"PHASE4":860,"NA":862},{"trials":839,"activeCount":98},[],{"trials":841,"activeCount":94,"soonestReadout":846},[842],{"nctId":843,"briefTitle":844,"status":153,"phases":845,"primaryCompletion":846,"completion":846,"start":847,"enrollment":848,"conditions":849,"interventions":851},"NCT06976892","Investigating Idetrexed and Olaparib in Patients With Ovarian Cancer",[86],"2029-12","2025-08",33,[850],"High Grade Serous Ovarian Cancer",[836,852,853,854,855],"Dose Level 1","Dose Level -1","Dose Level 3","Maximum Tolerated Dose",{"trials":857,"activeCount":98},[],{"trials":859,"activeCount":98},[],{"trials":861,"activeCount":98},[],{"trials":863,"activeCount":98},[],{"intervention":852,"totalTrials":94,"cells":865},{"EARLY_PHASE1":866,"PHASE1":868,"PHASE2":874,"PHASE3":876,"PHASE4":878,"NA":880},{"trials":867,"activeCount":98},[],{"trials":869,"activeCount":94,"soonestReadout":846},[870],{"nctId":843,"briefTitle":844,"status":153,"phases":871,"primaryCompletion":846,"completion":846,"start":847,"enrollment":848,"conditions":872,"interventions":873},[86],[850],[836,852,853,854,855],{"trials":875,"activeCount":98},[],{"trials":877,"activeCount":98},[],{"trials":879,"activeCount":98},[],{"trials":881,"activeCount":98},[],{"intervention":853,"totalTrials":94,"cells":883},{"EARLY_PHASE1":884,"PHASE1":886,"PHASE2":892,"PHASE3":894,"PHASE4":896,"NA":898},{"trials":885,"activeCount":98},[],{"trials":887,"activeCount":94,"soonestReadout":846},[888],{"nctId":843,"briefTitle":844,"status":153,"phases":889,"primaryCompletion":846,"completion":846,"start":847,"enrollment":848,"conditions":890,"interventions":891},[86],[850],[836,852,853,854,855],{"trials":893,"activeCount":98},[],{"trials":895,"activeCount":98},[],{"trials":897,"activeCount":98},[],{"trials":899,"activeCount":98},[],{"intervention":854,"totalTrials":94,"cells":901},{"EARLY_PHASE1":902,"PHASE1":904,"PHASE2":910,"PHASE3":912,"PHASE4":914,"NA":916},{"trials":903,"activeCount":98},[],{"trials":905,"activeCount":94,"soonestReadout":846},[906],{"nctId":843,"briefTitle":844,"status":153,"phases":907,"primaryCompletion":846,"completion":846,"start":847,"enrollment":848,"conditions":908,"interventions":909},[86],[850],[836,852,853,854,855],{"trials":911,"activeCount":98},[],{"trials":913,"activeCount":98},[],{"trials":915,"activeCount":98},[],{"trials":917,"activeCount":98},[],{"intervention":855,"totalTrials":94,"cells":919},{"EARLY_PHASE1":920,"PHASE1":922,"PHASE2":928,"PHASE3":930,"PHASE4":932,"NA":934},{"trials":921,"activeCount":98},[],{"trials":923,"activeCount":94,"soonestReadout":846},[924],{"nctId":843,"briefTitle":844,"status":153,"phases":925,"primaryCompletion":846,"completion":846,"start":847,"enrollment":848,"conditions":926,"interventions":927},[86],[850],[836,852,853,854,855],{"trials":929,"activeCount":98},[],{"trials":931,"activeCount":98},[],{"trials":933,"activeCount":98},[],{"trials":935,"activeCount":98},[],{"intervention":760,"totalTrials":94,"cells":937},{"EARLY_PHASE1":938,"PHASE1":940,"PHASE2":946,"PHASE3":948,"PHASE4":950,"NA":952},{"trials":939,"activeCount":98},[],{"trials":941,"activeCount":94,"soonestReadout":753},[942],{"nctId":750,"briefTitle":751,"status":108,"phases":943,"primaryCompletion":753,"completion":754,"start":755,"enrollment":9,"conditions":944,"interventions":945},[86],[757,758],[760,743],{"trials":947,"activeCount":98},[],{"trials":949,"activeCount":98},[],{"trials":951,"activeCount":98},[],{"trials":953,"activeCount":98},[],{"intervention":68,"totalTrials":94,"cells":955},{"EARLY_PHASE1":956,"PHASE1":958,"PHASE2":964,"PHASE3":966,"PHASE4":968,"NA":970},{"trials":957,"activeCount":98},[],{"trials":959,"activeCount":94,"soonestReadout":67},[960],{"nctId":65,"briefTitle":66,"status":153,"phases":961,"primaryCompletion":67,"completion":67,"start":763,"enrollment":764,"conditions":962,"interventions":963},[86],[757,766,33],[68,743],{"trials":965,"activeCount":98},[],{"trials":967,"activeCount":98},[],{"trials":969,"activeCount":98},[],{"trials":971,"activeCount":98},[],{"intervention":39,"totalTrials":259,"cells":973},{"EARLY_PHASE1":974,"PHASE1":976,"PHASE2":978,"PHASE3":980,"PHASE4":982,"NA":984},{"trials":975,"activeCount":98},[],{"trials":977,"activeCount":98},[],{"trials":979,"activeCount":98},[],{"trials":981,"activeCount":98},[],{"trials":983,"activeCount":98},[],{"trials":985,"activeCount":259,"soonestReadout":38},[986,992],{"nctId":51,"briefTitle":52,"status":108,"phases":987,"primaryCompletion":53,"completion":405,"start":988,"enrollment":989,"conditions":990,"interventions":991},[],"2019-03-14",4700,[17],[39],{"nctId":36,"briefTitle":37,"status":108,"phases":993,"primaryCompletion":38,"completion":405,"start":994,"enrollment":995,"conditions":996,"interventions":997},[],"2016-04-29",329,[17],[39],{"intervention":999,"totalTrials":94,"cells":1000},"The i4i PRODICT® test.",{"EARLY_PHASE1":1001,"PHASE1":1003,"PHASE2":1005,"PHASE3":1007,"PHASE4":1009,"NA":1011},{"trials":1002,"activeCount":98},[],{"trials":1004,"activeCount":98},[],{"trials":1006,"activeCount":98},[],{"trials":1008,"activeCount":98},[],{"trials":1010,"activeCount":98},[],{"trials":1012,"activeCount":94,"soonestReadout":1017},[1013],{"nctId":1014,"briefTitle":1015,"status":153,"phases":1016,"primaryCompletion":1017,"completion":1018,"start":1019,"enrollment":1020,"conditions":1021,"interventions":1022},"NCT06636526","The i4i PRODICT® Study: Evaluation of the i4i PRODICT® Test in Different Ethnic Groups (The i4i PRODICT® Study).",[],"2028-12-01","2033-01-06","2025-06-02",1000,[17],[999],{"intervention":1024,"totalTrials":94,"cells":1025},"Prostate cancer risk gene panel",{"EARLY_PHASE1":1026,"PHASE1":1028,"PHASE2":1030,"PHASE3":1032,"PHASE4":1034,"NA":1036},{"trials":1027,"activeCount":98},[],{"trials":1029,"activeCount":98},[],{"trials":1031,"activeCount":98},[],{"trials":1033,"activeCount":98},[],{"trials":1035,"activeCount":98},[],{"trials":1037,"activeCount":94,"soonestReadout":1042},[1038],{"nctId":1039,"briefTitle":1040,"status":153,"phases":1041,"primaryCompletion":1042,"completion":1043,"start":1044,"enrollment":1045,"conditions":1046,"interventions":1048},"NCT04763317","Precision Medicine in the Prostate Cancer Care Pathway",[],"2029-12-31","2034-12","2019-02-14",3000,[17,1047],"Genetic Predisposition",[1024],{"intervention":1050,"totalTrials":283,"cells":1051},"cyclophosphamide",{"EARLY_PHASE1":1052,"PHASE1":1054,"PHASE2":1056,"PHASE3":1082,"PHASE4":1107,"NA":1109},{"trials":1053,"activeCount":98},[],{"trials":1055,"activeCount":98},[],{"trials":1057,"activeCount":98},[1058,1071],{"nctId":1059,"briefTitle":1060,"status":305,"phases":1061,"start":1062,"conditions":1063,"interventions":1064},"NCT00033683","Combination Chemotherapy in Treating Women With Resected Breast Cancer",[87],"2001-02",[14],[1065,1050,1066,1067,1068,1069,1070],"CMF regimen","docetaxel","epirubicin hydrochloride","fluorouracil","methotrexate","tamoxifen citrate",{"nctId":1072,"briefTitle":1073,"status":265,"phases":1074,"completion":1075,"start":268,"enrollment":1076,"conditions":1077,"interventions":1079},"NCT00053092","Combination Chemotherapy With or Without Rituximab in Treating Patients With Mantle Cell Lymphoma",[87],"2009-02",82,[1078],"Lymphoma",[1080,1050,1081],"rituximab","fludarabine phosphate",{"trials":1083,"activeCount":98},[1084,1095],{"nctId":1085,"briefTitle":1086,"status":305,"phases":1087,"primaryCompletion":1088,"completion":1088,"start":1089,"enrollment":1090,"conditions":1091,"interventions":1092},"NCT00301925","Combination Chemotherapy in Treating Patients With Early Stage Breast Cancer That Has Been Removed By Surgery",[88],"2024-09","2005-12-16",4400,[14],[1093,1094,1050,1067,1068,1069],"pegfilgrastim","capecitabine",{"nctId":1096,"briefTitle":1097,"status":265,"phases":1098,"completion":1099,"start":1100,"enrollment":1101,"conditions":1102,"interventions":1103},"NCT00002582","Tamoxifen, Ovarian Ablation, and\u002For Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer",[88],"2007-04","1993-06",6000,[14],[1065,1050,1104,1068,1105,1106,1069,1070],"doxorubicin hydrochloride","goserelin acetate","leuprolide acetate",{"trials":1108,"activeCount":98},[],{"trials":1110,"activeCount":98},[],{"intervention":1068,"totalTrials":283,"cells":1112},{"EARLY_PHASE1":1113,"PHASE1":1115,"PHASE2":1117,"PHASE3":1123,"PHASE4":1143,"NA":1145},{"trials":1114,"activeCount":98},[],{"trials":1116,"activeCount":98},[],{"trials":1118,"activeCount":98},[1119],{"nctId":1059,"briefTitle":1060,"status":305,"phases":1120,"start":1062,"conditions":1121,"interventions":1122},[87],[14],[1065,1050,1066,1067,1068,1069,1070],{"trials":1124,"activeCount":98},[1125,1129,1139],{"nctId":1085,"briefTitle":1086,"status":305,"phases":1126,"primaryCompletion":1088,"completion":1088,"start":1089,"enrollment":1090,"conditions":1127,"interventions":1128},[88],[14],[1093,1094,1050,1067,1068,1069],{"nctId":1130,"briefTitle":1131,"status":265,"phases":1132,"start":1133,"enrollment":1134,"conditions":1135,"interventions":1137},"NCT00005586","Leucovorin and Fluorouracil Compared With Observation in Treating Patients With Colorectal Cancer That Has Been Surgically Removed",[88],"1997-10",2500,[1136],"Colorectal Cancer",[1138,1068],"L-leucovorin",{"nctId":1096,"briefTitle":1097,"status":265,"phases":1140,"completion":1099,"start":1100,"enrollment":1101,"conditions":1141,"interventions":1142},[88],[14],[1065,1050,1104,1068,1105,1106,1069,1070],{"trials":1144,"activeCount":98},[],{"trials":1146,"activeCount":98},[],{"intervention":1069,"totalTrials":27,"cells":1148},{"EARLY_PHASE1":1149,"PHASE1":1151,"PHASE2":1153,"PHASE3":1159,"PHASE4":1169,"NA":1171},{"trials":1150,"activeCount":98},[],{"trials":1152,"activeCount":98},[],{"trials":1154,"activeCount":98},[1155],{"nctId":1059,"briefTitle":1060,"status":305,"phases":1156,"start":1062,"conditions":1157,"interventions":1158},[87],[14],[1065,1050,1066,1067,1068,1069,1070],{"trials":1160,"activeCount":98},[1161,1165],{"nctId":1085,"briefTitle":1086,"status":305,"phases":1162,"primaryCompletion":1088,"completion":1088,"start":1089,"enrollment":1090,"conditions":1163,"interventions":1164},[88],[14],[1093,1094,1050,1067,1068,1069],{"nctId":1096,"briefTitle":1097,"status":265,"phases":1166,"completion":1099,"start":1100,"enrollment":1101,"conditions":1167,"interventions":1168},[88],[14],[1065,1050,1104,1068,1105,1106,1069,1070],{"trials":1170,"activeCount":98},[],{"trials":1172,"activeCount":98},[],{"intervention":1070,"totalTrials":27,"cells":1174},{"EARLY_PHASE1":1175,"PHASE1":1177,"PHASE2":1179,"PHASE3":1195,"PHASE4":1201,"NA":1203},{"trials":1176,"activeCount":98},[],{"trials":1178,"activeCount":98},[],{"trials":1180,"activeCount":98},[1181,1185],{"nctId":1059,"briefTitle":1060,"status":305,"phases":1182,"start":1062,"conditions":1183,"interventions":1184},[87],[14],[1065,1050,1066,1067,1068,1069,1070],{"nctId":1186,"briefTitle":1187,"status":305,"phases":1188,"primaryCompletion":1189,"start":1190,"enrollment":1191,"conditions":1192,"interventions":1193},"NCT00077168","Adjuvant Radiation Therapy Compared With Observation After Surgery in Treating Women With Estrogen Receptor Positive or Progesterone Receptor Positive Ductal Carcinoma In Situ of the Breast Who Are Receiving Tamoxifen or Anastrozole",[87],"2017-09","2004-04",2000,[14],[1194,1070],"anastrozole",{"trials":1196,"activeCount":98},[1197],{"nctId":1096,"briefTitle":1097,"status":265,"phases":1198,"completion":1099,"start":1100,"enrollment":1101,"conditions":1199,"interventions":1200},[88],[14],[1065,1050,1104,1068,1105,1106,1069,1070],{"trials":1202,"activeCount":98},[],{"trials":1204,"activeCount":98},[],{"intervention":1065,"totalTrials":259,"cells":1206},{"EARLY_PHASE1":1207,"PHASE1":1209,"PHASE2":1211,"PHASE3":1217,"PHASE4":1223,"NA":1225},{"trials":1208,"activeCount":98},[],{"trials":1210,"activeCount":98},[],{"trials":1212,"activeCount":98},[1213],{"nctId":1059,"briefTitle":1060,"status":305,"phases":1214,"start":1062,"conditions":1215,"interventions":1216},[87],[14],[1065,1050,1066,1067,1068,1069,1070],{"trials":1218,"activeCount":98},[1219],{"nctId":1096,"briefTitle":1097,"status":265,"phases":1220,"completion":1099,"start":1100,"enrollment":1101,"conditions":1221,"interventions":1222},[88],[14],[1065,1050,1104,1068,1105,1106,1069,1070],{"trials":1224,"activeCount":98},[],{"trials":1226,"activeCount":98},[],{"intervention":1066,"totalTrials":259,"cells":1228},{"EARLY_PHASE1":1229,"PHASE1":1231,"PHASE2":1233,"PHASE3":1239,"PHASE4":1245,"NA":1247},{"trials":1230,"activeCount":98},[],{"trials":1232,"activeCount":98},[],{"trials":1234,"activeCount":98},[1235],{"nctId":1059,"briefTitle":1060,"status":305,"phases":1236,"start":1062,"conditions":1237,"interventions":1238},[87],[14],[1065,1050,1066,1067,1068,1069,1070],{"trials":1240,"activeCount":98},[1241],{"nctId":414,"briefTitle":415,"status":305,"phases":1242,"primaryCompletion":417,"completion":418,"start":419,"enrollment":420,"conditions":1243,"interventions":1244},[88],[14],[392,423],{"trials":1246,"activeCount":98},[],{"trials":1248,"activeCount":98},[],{"intervention":1067,"totalTrials":259,"cells":1250},{"EARLY_PHASE1":1251,"PHASE1":1253,"PHASE2":1255,"PHASE3":1261,"PHASE4":1267,"NA":1269},{"trials":1252,"activeCount":98},[],{"trials":1254,"activeCount":98},[],{"trials":1256,"activeCount":98},[1257],{"nctId":1059,"briefTitle":1060,"status":305,"phases":1258,"start":1062,"conditions":1259,"interventions":1260},[87],[14],[1065,1050,1066,1067,1068,1069,1070],{"trials":1262,"activeCount":98},[1263],{"nctId":1085,"briefTitle":1086,"status":305,"phases":1264,"primaryCompletion":1088,"completion":1088,"start":1089,"enrollment":1090,"conditions":1265,"interventions":1266},[88],[14],[1093,1094,1050,1067,1068,1069],{"trials":1268,"activeCount":98},[],{"trials":1270,"activeCount":98},[],{"intervention":1194,"totalTrials":259,"cells":1272},{"EARLY_PHASE1":1273,"PHASE1":1275,"PHASE2":1277,"PHASE3":1283,"PHASE4":1296,"NA":1298},{"trials":1274,"activeCount":98},[],{"trials":1276,"activeCount":98},[],{"trials":1278,"activeCount":98},[1279],{"nctId":1186,"briefTitle":1187,"status":305,"phases":1280,"primaryCompletion":1189,"start":1190,"enrollment":1191,"conditions":1281,"interventions":1282},[87],[14],[1194,1070],{"trials":1284,"activeCount":98},[1285],{"nctId":1286,"briefTitle":1287,"status":265,"phases":1288,"primaryCompletion":1289,"completion":1289,"start":1290,"enrollment":1291,"conditions":1292,"interventions":1293},"NCT00253422","Study of Faslodex +\u002F- Concomitant Arimidex v Exemestane Following Progression on Non-steroidal Aromatase Inhibitors",[88],"2022-11-28","2004-03-26",698,[14],[1294,1295,314],"Anastrozole","Exemestane",{"trials":1297,"activeCount":98},[],{"trials":1299,"activeCount":98},[],{"intervention":314,"totalTrials":259,"cells":1301},{"EARLY_PHASE1":1302,"PHASE1":1304,"PHASE2":1306,"PHASE3":1312,"PHASE4":1318,"NA":1320},{"trials":1303,"activeCount":98},[],{"trials":1305,"activeCount":98},[],{"trials":1307,"activeCount":98},[1308],{"nctId":303,"briefTitle":304,"status":305,"phases":1309,"primaryCompletion":307,"completion":308,"start":309,"enrollment":310,"conditions":1310,"interventions":1311},[87],[312],[314,315,316,282,83],{"trials":1313,"activeCount":98},[1314],{"nctId":1286,"briefTitle":1287,"status":265,"phases":1315,"primaryCompletion":1289,"completion":1289,"start":1290,"enrollment":1291,"conditions":1316,"interventions":1317},[88],[14],[1294,1295,314],{"trials":1319,"activeCount":98},[],{"trials":1321,"activeCount":98},[],{"intervention":1323,"totalTrials":94,"cells":1324},"trastuzumab",{"EARLY_PHASE1":1325,"PHASE1":1327,"PHASE2":1329,"PHASE3":1331,"PHASE4":1344,"NA":1346},{"trials":1326,"activeCount":98},[],{"trials":1328,"activeCount":98},[],{"trials":1330,"activeCount":98},[],{"trials":1332,"activeCount":98},[1333],{"nctId":1334,"briefTitle":1335,"status":305,"phases":1336,"primaryCompletion":1337,"completion":1338,"start":1339,"enrollment":1340,"conditions":1341,"interventions":1342},"NCT01104571","Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast Cancer",[88],"2017-08-30","2025-09","2010-04",257,[14],[1323,1343],"lapatinib ditosylate",{"trials":1345,"activeCount":98},[],{"trials":1347,"activeCount":98},[],{"intervention":1343,"totalTrials":94,"cells":1349},{"EARLY_PHASE1":1350,"PHASE1":1352,"PHASE2":1354,"PHASE3":1356,"PHASE4":1362,"NA":1364},{"trials":1351,"activeCount":98},[],{"trials":1353,"activeCount":98},[],{"trials":1355,"activeCount":98},[],{"trials":1357,"activeCount":98},[1358],{"nctId":1334,"briefTitle":1335,"status":305,"phases":1359,"primaryCompletion":1337,"completion":1338,"start":1339,"enrollment":1340,"conditions":1360,"interventions":1361},[88],[14],[1323,1343],{"trials":1363,"activeCount":98},[],{"trials":1365,"activeCount":98},[],{"intervention":1367,"totalTrials":94,"cells":1368},"TKI",{"EARLY_PHASE1":1369,"PHASE1":1371,"PHASE2":1373,"PHASE3":1375,"PHASE4":1387,"NA":1389},{"trials":1370,"activeCount":98},[],{"trials":1372,"activeCount":98},[],{"trials":1374,"activeCount":98},[],{"trials":1376,"activeCount":98},[1377],{"nctId":1378,"briefTitle":1379,"status":305,"phases":1380,"primaryCompletion":1381,"completion":1382,"start":1383,"enrollment":1384,"conditions":1385,"interventions":1386},"NCT03256981","Stereotactic Body Radiotherapy for the Treatment of OPD",[87,88],"2023-07-17","2025-06-30","2017-11-27",113,[374],[1367],{"trials":1388,"activeCount":98},[],{"trials":1390,"activeCount":98},[],{"intervention":1093,"totalTrials":94,"cells":1392},{"EARLY_PHASE1":1393,"PHASE1":1395,"PHASE2":1397,"PHASE3":1399,"PHASE4":1405,"NA":1407},{"trials":1394,"activeCount":98},[],{"trials":1396,"activeCount":98},[],{"trials":1398,"activeCount":98},[],{"trials":1400,"activeCount":98},[1401],{"nctId":1085,"briefTitle":1086,"status":305,"phases":1402,"primaryCompletion":1088,"completion":1088,"start":1089,"enrollment":1090,"conditions":1403,"interventions":1404},[88],[14],[1093,1094,1050,1067,1068,1069],{"trials":1406,"activeCount":98},[],{"trials":1408,"activeCount":98},[],{"intervention":1094,"totalTrials":94,"cells":1410},{"EARLY_PHASE1":1411,"PHASE1":1413,"PHASE2":1415,"PHASE3":1417,"PHASE4":1423,"NA":1425},{"trials":1412,"activeCount":98},[],{"trials":1414,"activeCount":98},[],{"trials":1416,"activeCount":98},[],{"trials":1418,"activeCount":98},[1419],{"nctId":1085,"briefTitle":1086,"status":305,"phases":1420,"primaryCompletion":1088,"completion":1088,"start":1089,"enrollment":1090,"conditions":1421,"interventions":1422},[88],[14],[1093,1094,1050,1067,1068,1069],{"trials":1424,"activeCount":98},[],{"trials":1426,"activeCount":98},[],{"intervention":1138,"totalTrials":94,"cells":1428},{"EARLY_PHASE1":1429,"PHASE1":1431,"PHASE2":1433,"PHASE3":1435,"PHASE4":1441,"NA":1443},{"trials":1430,"activeCount":98},[],{"trials":1432,"activeCount":98},[],{"trials":1434,"activeCount":98},[],{"trials":1436,"activeCount":98},[1437],{"nctId":1130,"briefTitle":1131,"status":265,"phases":1438,"start":1133,"enrollment":1134,"conditions":1439,"interventions":1440},[88],[1136],[1138,1068],{"trials":1442,"activeCount":98},[],{"trials":1444,"activeCount":98},[],{"intervention":273,"totalTrials":94,"cells":1446},{"EARLY_PHASE1":1447,"PHASE1":1449,"PHASE2":1451,"PHASE3":1453,"PHASE4":1459,"NA":1461},{"trials":1448,"activeCount":98},[],{"trials":1450,"activeCount":98},[],{"trials":1452,"activeCount":98},[],{"trials":1454,"activeCount":98},[1455],{"nctId":263,"briefTitle":264,"status":265,"phases":1456,"completion":267,"start":268,"enrollment":269,"conditions":1457,"interventions":1458},[88],[271],[273,274,275,276],{"trials":1460,"activeCount":98},[],{"trials":1462,"activeCount":98},[],{"intervention":274,"totalTrials":94,"cells":1464},{"EARLY_PHASE1":1465,"PHASE1":1467,"PHASE2":1469,"PHASE3":1471,"PHASE4":1477,"NA":1479},{"trials":1466,"activeCount":98},[],{"trials":1468,"activeCount":98},[],{"trials":1470,"activeCount":98},[],{"trials":1472,"activeCount":98},[1473],{"nctId":263,"briefTitle":264,"status":265,"phases":1474,"completion":267,"start":268,"enrollment":269,"conditions":1475,"interventions":1476},[88],[271],[273,274,275,276],{"trials":1478,"activeCount":98},[],{"trials":1480,"activeCount":98},[],{"intervention":276,"totalTrials":94,"cells":1482},{"EARLY_PHASE1":1483,"PHASE1":1485,"PHASE2":1487,"PHASE3":1489,"PHASE4":1495,"NA":1497},{"trials":1484,"activeCount":98},[],{"trials":1486,"activeCount":98},[],{"trials":1488,"activeCount":98},[],{"trials":1490,"activeCount":98},[1491],{"nctId":263,"briefTitle":264,"status":265,"phases":1492,"completion":267,"start":268,"enrollment":269,"conditions":1493,"interventions":1494},[88],[271],[273,274,275,276],{"trials":1496,"activeCount":98},[],{"trials":1498,"activeCount":98},[],{"intervention":1295,"totalTrials":94,"cells":1500},{"EARLY_PHASE1":1501,"PHASE1":1503,"PHASE2":1505,"PHASE3":1507,"PHASE4":1513,"NA":1515},{"trials":1502,"activeCount":98},[],{"trials":1504,"activeCount":98},[],{"trials":1506,"activeCount":98},[],{"trials":1508,"activeCount":98},[1509],{"nctId":1286,"briefTitle":1287,"status":265,"phases":1510,"primaryCompletion":1289,"completion":1289,"start":1290,"enrollment":1291,"conditions":1511,"interventions":1512},[88],[14],[1294,1295,314],{"trials":1514,"activeCount":98},[],{"trials":1516,"activeCount":98},[],{"intervention":1104,"totalTrials":94,"cells":1518},{"EARLY_PHASE1":1519,"PHASE1":1521,"PHASE2":1523,"PHASE3":1525,"PHASE4":1531,"NA":1533},{"trials":1520,"activeCount":98},[],{"trials":1522,"activeCount":98},[],{"trials":1524,"activeCount":98},[],{"trials":1526,"activeCount":98},[1527],{"nctId":1096,"briefTitle":1097,"status":265,"phases":1528,"completion":1099,"start":1100,"enrollment":1101,"conditions":1529,"interventions":1530},[88],[14],[1065,1050,1104,1068,1105,1106,1069,1070],{"trials":1532,"activeCount":98},[],{"trials":1534,"activeCount":98},[],{"intervention":1106,"totalTrials":94,"cells":1536},{"EARLY_PHASE1":1537,"PHASE1":1539,"PHASE2":1541,"PHASE3":1543,"PHASE4":1549,"NA":1551},{"trials":1538,"activeCount":98},[],{"trials":1540,"activeCount":98},[],{"trials":1542,"activeCount":98},[],{"trials":1544,"activeCount":98},[1545],{"nctId":1096,"briefTitle":1097,"status":265,"phases":1546,"completion":1099,"start":1100,"enrollment":1101,"conditions":1547,"interventions":1548},[88],[14],[1065,1050,1104,1068,1105,1106,1069,1070],{"trials":1550,"activeCount":98},[],{"trials":1552,"activeCount":98},[],{"intervention":1554,"totalTrials":94,"cells":1555},"recombinant interferon alfa",{"EARLY_PHASE1":1556,"PHASE1":1558,"PHASE2":1560,"PHASE3":1562,"PHASE4":1573,"NA":1575},{"trials":1557,"activeCount":98},[],{"trials":1559,"activeCount":98},[],{"trials":1561,"activeCount":98},[],{"trials":1563,"activeCount":98},[1564],{"nctId":1565,"briefTitle":1566,"status":265,"phases":1567,"completion":1568,"start":1569,"enrollment":1020,"conditions":1570,"interventions":1572},"NCT00002892","Interferon Alfa or No Further Therapy Following Surgery in Treating Patients With Stage II, Stage III, or Recurrent Melanoma",[88],"2001-12","1995-10",[1571],"Melanoma (Skin)",[1554],{"trials":1574,"activeCount":98},[],{"trials":1576,"activeCount":98},[],{"intervention":1578,"totalTrials":94,"cells":1579},"BEP",{"EARLY_PHASE1":1580,"PHASE1":1582,"PHASE2":1584,"PHASE3":1586,"PHASE4":1598,"NA":1600},{"trials":1581,"activeCount":98},[],{"trials":1583,"activeCount":98},[],{"trials":1585,"activeCount":98},[],{"trials":1587,"activeCount":98},[1588],{"nctId":1589,"briefTitle":1590,"status":265,"phases":1591,"primaryCompletion":1592,"completion":1088,"start":1593,"enrollment":1594,"conditions":1595,"interventions":1597},"NCT01726374","Trial of 1 Cycle of Adjuvant BEP Chemotherapy in High Risk, Stage 1 Non-seminomatous Germ Cell Testis Tumours",[88],"2016-08","2010-02",246,[1596],"Stage I Testicular Non-Seminomatous Germ Cell Tumor",[1578],{"trials":1599,"activeCount":98},[],{"trials":1601,"activeCount":98},[],{"intervention":316,"totalTrials":259,"cells":1603},{"EARLY_PHASE1":1604,"PHASE1":1606,"PHASE2":1608,"PHASE3":1624,"PHASE4":1626,"NA":1628},{"trials":1605,"activeCount":98},[],{"trials":1607,"activeCount":98},[],{"trials":1609,"activeCount":98},[1610,1614],{"nctId":303,"briefTitle":304,"status":305,"phases":1611,"primaryCompletion":307,"completion":308,"start":309,"enrollment":310,"conditions":1612,"interventions":1613},[87],[312],[314,315,316,282,83],{"nctId":1615,"briefTitle":1616,"status":305,"phases":1617,"primaryCompletion":1618,"completion":418,"start":1619,"enrollment":1620,"conditions":1621,"interventions":1622},"NCT02525068","A Study of Enzalutamide in Combination With AZD5363 in Patients With mCRPC",[87],"2019-12-31","2014-12",136,[31],[316,1623],"Enzalutamide",{"trials":1625,"activeCount":98},[],{"trials":1627,"activeCount":98},[],{"trials":1629,"activeCount":98},[],{"intervention":1631,"totalTrials":94,"cells":1632},"Abiraterone Acetate",{"EARLY_PHASE1":1633,"PHASE1":1635,"PHASE2":1637,"PHASE3":1652,"PHASE4":1654,"NA":1656},{"trials":1634,"activeCount":98},[],{"trials":1636,"activeCount":98},[],{"trials":1638,"activeCount":98},[1639],{"nctId":1640,"briefTitle":1641,"status":1642,"phases":1643,"primaryCompletion":1644,"completion":1645,"start":1646,"enrollment":1647,"conditions":1648,"interventions":1650},"NCT04458311","Abiraterone Acetate in Combination With Tildrakizumab","TERMINATED",[86,87],"2023-04-01","2023-11-15","2020-12-01",13,[1649],"Metastatic Castration Resistant Prostate Cancer",[1631,1651],"Tildrakizumab",{"trials":1653,"activeCount":98},[],{"trials":1655,"activeCount":98},[],{"trials":1657,"activeCount":98},[],{"intervention":1651,"totalTrials":94,"cells":1659},{"EARLY_PHASE1":1660,"PHASE1":1662,"PHASE2":1664,"PHASE3":1670,"PHASE4":1672,"NA":1674},{"trials":1661,"activeCount":98},[],{"trials":1663,"activeCount":98},[],{"trials":1665,"activeCount":98},[1666],{"nctId":1640,"briefTitle":1641,"status":1642,"phases":1667,"primaryCompletion":1644,"completion":1645,"start":1646,"enrollment":1647,"conditions":1668,"interventions":1669},[86,87],[1649],[1631,1651],{"trials":1671,"activeCount":98},[],{"trials":1673,"activeCount":98},[],{"trials":1675,"activeCount":98},[],{"intervention":1677,"totalTrials":94,"cells":1678},"Lapatinib",{"EARLY_PHASE1":1679,"PHASE1":1681,"PHASE2":1683,"PHASE3":1695,"PHASE4":1697,"NA":1699},{"trials":1680,"activeCount":98},[],{"trials":1682,"activeCount":98},[],{"trials":1684,"activeCount":98},[1685],{"nctId":1686,"briefTitle":1687,"status":265,"phases":1688,"primaryCompletion":1689,"completion":1689,"start":1690,"enrollment":1691,"conditions":1692,"interventions":1693},"NCT00299286","Short-term Presurgical Study to Assess Molecular Predictors of Lapatinib's Effects in Primary Breast Cancer",[87],"2011-08","2007-06",121,[14],[1677,1694],"Lapatinib-Placebo",{"trials":1696,"activeCount":98},[],{"trials":1698,"activeCount":98},[],{"trials":1700,"activeCount":98},[],{"intervention":1694,"totalTrials":94,"cells":1702},{"EARLY_PHASE1":1703,"PHASE1":1705,"PHASE2":1707,"PHASE3":1713,"PHASE4":1715,"NA":1717},{"trials":1704,"activeCount":98},[],{"trials":1706,"activeCount":98},[],{"trials":1708,"activeCount":98},[1709],{"nctId":1686,"briefTitle":1687,"status":265,"phases":1710,"primaryCompletion":1689,"completion":1689,"start":1690,"enrollment":1691,"conditions":1711,"interventions":1712},[87],[14],[1677,1694],{"trials":1714,"activeCount":98},[],{"trials":1716,"activeCount":98},[],{"trials":1718,"activeCount":98},[],{"intervention":1720,"totalTrials":94,"cells":1721},"hyperbaric oxygen",{"EARLY_PHASE1":1722,"PHASE1":1724,"PHASE2":1726,"PHASE3":1738,"PHASE4":1740,"NA":1742},{"trials":1723,"activeCount":98},[],{"trials":1725,"activeCount":98},[],{"trials":1727,"activeCount":98},[1728],{"nctId":1729,"briefTitle":1730,"status":305,"phases":1731,"start":1190,"enrollment":1732,"conditions":1733,"interventions":1737},"NCT00077090","Hyperbaric Oxygen Therapy Compared With Standard Therapy in Treating Chronic Arm Lymphedema in Patients Who Have Undergone Radiation Therapy for Cancer",[87],63,[14,1734,1735,1736],"Lymphedema","Perioperative\u002FPostoperative Complications","Radiation Fibrosis",[1720],{"trials":1739,"activeCount":98},[],{"trials":1741,"activeCount":98},[],{"trials":1743,"activeCount":98},[],{"intervention":1745,"totalTrials":94,"cells":1746},"Vinflunine",{"EARLY_PHASE1":1747,"PHASE1":1749,"PHASE2":1751,"PHASE3":1763,"PHASE4":1765,"NA":1767},{"trials":1748,"activeCount":98},[],{"trials":1750,"activeCount":98},[],{"trials":1752,"activeCount":98},[1753],{"nctId":1754,"briefTitle":1755,"status":265,"phases":1756,"primaryCompletion":1757,"completion":1757,"start":1758,"enrollment":1759,"conditions":1760,"interventions":1762},"NCT02057913","A Phase II Trial of Vinflunine Chemotherapy in Locally-advanced and Metastatic Carcinoma of the Penis (VinCaP)",[87],"2018-11-06","2014-03-17",22,[1761],"Locally-advanced or Metastatic Penile Neoplasms",[1745],{"trials":1764,"activeCount":98},[],{"trials":1766,"activeCount":98},[],{"trials":1768,"activeCount":98},[],{"intervention":315,"totalTrials":94,"cells":1770},{"EARLY_PHASE1":1771,"PHASE1":1773,"PHASE2":1775,"PHASE3":1781,"PHASE4":1783,"NA":1785},{"trials":1772,"activeCount":98},[],{"trials":1774,"activeCount":98},[],{"trials":1776,"activeCount":98},[1777],{"nctId":303,"briefTitle":304,"status":305,"phases":1778,"primaryCompletion":307,"completion":308,"start":309,"enrollment":310,"conditions":1779,"interventions":1780},[87],[312],[314,315,316,282,83],{"trials":1782,"activeCount":98},[],{"trials":1784,"activeCount":98},[],{"trials":1786,"activeCount":98},[],{"intervention":1788,"totalTrials":94,"cells":1789},"nilotinib",{"EARLY_PHASE1":1790,"PHASE1":1792,"PHASE2":1794,"PHASE3":1807,"PHASE4":1809,"NA":1811},{"trials":1791,"activeCount":98},[],{"trials":1793,"activeCount":98},[],{"trials":1795,"activeCount":98},[1796],{"nctId":1797,"briefTitle":1798,"status":265,"phases":1799,"primaryCompletion":1800,"completion":1800,"start":1801,"enrollment":1802,"conditions":1803,"interventions":1806},"NCT01395121","A Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has Spread",[87],"2016-12-12","2009-12",29,[1804,1805],"Mucosal Lentiginous Melanoma","Acral Lentiginous Malignant Melanoma",[1788],{"trials":1808,"activeCount":98},[],{"trials":1810,"activeCount":98},[],{"trials":1812,"activeCount":98},[],{"intervention":1814,"totalTrials":94,"cells":1815},"Axitinib",{"EARLY_PHASE1":1816,"PHASE1":1818,"PHASE2":1820,"PHASE3":1833,"PHASE4":1835,"NA":1837},{"trials":1817,"activeCount":98},[],{"trials":1819,"activeCount":98},[],{"trials":1821,"activeCount":98},[1822],{"nctId":1823,"briefTitle":1824,"status":265,"phases":1825,"primaryCompletion":1826,"completion":1827,"start":1828,"enrollment":1829,"conditions":1830,"interventions":1832},"NCT01693822","A Phase II Study of Axitinib in Patients With Metastatic Renal Cell Cancer Unsuitable for Nephrectomy",[87],"2017-03","2022-02-28","2012-10",65,[1831],"Clear-cell Metastatic Renal Cell Carcinoma",[1814],{"trials":1834,"activeCount":98},[],{"trials":1836,"activeCount":98},[],{"trials":1838,"activeCount":98},[],{"intervention":1840,"totalTrials":94,"cells":1841},"Cediranib",{"EARLY_PHASE1":1842,"PHASE1":1844,"PHASE2":1846,"PHASE3":1859,"PHASE4":1861,"NA":1863},{"trials":1843,"activeCount":98},[],{"trials":1845,"activeCount":98},[],{"trials":1847,"activeCount":98},[1848],{"nctId":1849,"briefTitle":1850,"status":305,"phases":1851,"primaryCompletion":1852,"completion":1853,"start":1854,"enrollment":1855,"conditions":1856,"interventions":1858},"NCT01337401","A Trial of Cediranib in the Treatment of Patients With Alveolar Soft Part Sarcoma (CASPS)",[87],"2019-07","2020-01","2011-07",36,[1857],"Alveolar Soft-part Sarcoma",[1840],{"trials":1860,"activeCount":98},[],{"trials":1862,"activeCount":98},[],{"trials":1864,"activeCount":98},[],{"intervention":1080,"totalTrials":94,"cells":1866},{"EARLY_PHASE1":1867,"PHASE1":1869,"PHASE2":1871,"PHASE3":1877,"PHASE4":1879,"NA":1881},{"trials":1868,"activeCount":98},[],{"trials":1870,"activeCount":98},[],{"trials":1872,"activeCount":98},[1873],{"nctId":1072,"briefTitle":1073,"status":265,"phases":1874,"completion":1075,"start":268,"enrollment":1076,"conditions":1875,"interventions":1876},[87],[1078],[1080,1050,1081],{"trials":1878,"activeCount":98},[],{"trials":1880,"activeCount":98},[],{"trials":1882,"activeCount":98},[],{"intervention":1081,"totalTrials":94,"cells":1884},{"EARLY_PHASE1":1885,"PHASE1":1887,"PHASE2":1889,"PHASE3":1895,"PHASE4":1897,"NA":1899},{"trials":1886,"activeCount":98},[],{"trials":1888,"activeCount":98},[],{"trials":1890,"activeCount":98},[1891],{"nctId":1072,"briefTitle":1073,"status":265,"phases":1892,"completion":1075,"start":268,"enrollment":1076,"conditions":1893,"interventions":1894},[87],[1078],[1080,1050,1081],{"trials":1896,"activeCount":98},[],{"trials":1898,"activeCount":98},[],{"trials":1900,"activeCount":98},[],{"intervention":1902,"totalTrials":94,"cells":1903},"AZD5069",{"EARLY_PHASE1":1904,"PHASE1":1906,"PHASE2":1908,"PHASE3":1921,"PHASE4":1923,"NA":1925},{"trials":1905,"activeCount":98},[],{"trials":1907,"activeCount":98},[],{"trials":1909,"activeCount":98},[1910],{"nctId":1911,"briefTitle":1912,"status":1642,"phases":1913,"primaryCompletion":1914,"completion":1915,"start":1916,"enrollment":1917,"conditions":1918,"interventions":1919},"NCT03177187","Combination Study of AZD5069 and Enzalutamide.",[86,87],"2022-09-15","2022-11-16","2017-11-13",30,[1649],[1902,1920],"Enzalutamide 40 MG",{"trials":1922,"activeCount":98},[],{"trials":1924,"activeCount":98},[],{"trials":1926,"activeCount":98},[],{"intervention":1920,"totalTrials":94,"cells":1928},{"EARLY_PHASE1":1929,"PHASE1":1931,"PHASE2":1933,"PHASE3":1939,"PHASE4":1941,"NA":1943},{"trials":1930,"activeCount":98},[],{"trials":1932,"activeCount":98},[],{"trials":1934,"activeCount":98},[1935],{"nctId":1911,"briefTitle":1912,"status":1642,"phases":1936,"primaryCompletion":1914,"completion":1915,"start":1916,"enrollment":1917,"conditions":1937,"interventions":1938},[86,87],[1649],[1902,1920],{"trials":1940,"activeCount":98},[],{"trials":1942,"activeCount":98},[],{"trials":1944,"activeCount":98},[],{"intervention":1623,"totalTrials":94,"cells":1946},{"EARLY_PHASE1":1947,"PHASE1":1949,"PHASE2":1951,"PHASE3":1957,"PHASE4":1959,"NA":1961},{"trials":1948,"activeCount":98},[],{"trials":1950,"activeCount":98},[],{"trials":1952,"activeCount":98},[1953],{"nctId":1615,"briefTitle":1616,"status":305,"phases":1954,"primaryCompletion":1618,"completion":418,"start":1619,"enrollment":1620,"conditions":1955,"interventions":1956},[87],[31],[316,1623],{"trials":1958,"activeCount":98},[],{"trials":1960,"activeCount":98},[],{"trials":1962,"activeCount":98},[],{"intervention":1964,"totalTrials":94,"cells":1965},"Mitomycin C",{"EARLY_PHASE1":1966,"PHASE1":1968,"PHASE2":1970,"PHASE3":1981,"PHASE4":1983,"NA":1985},{"trials":1967,"activeCount":98},[],{"trials":1969,"activeCount":98},[],{"trials":1971,"activeCount":98},[1972],{"nctId":1973,"briefTitle":1974,"status":305,"phases":1975,"primaryCompletion":1976,"completion":1977,"start":1978,"enrollment":1076,"conditions":1979,"interventions":1980},"NCT02070120","Investigating Bladder Chemotherapy Instead of Surgery for Low Risk Bladder Cancer",[87],"2018-01","2020-09","2014-10",[23],[1964],{"trials":1982,"activeCount":98},[],{"trials":1984,"activeCount":98},[],{"trials":1986,"activeCount":98},[],{"intervention":1988,"totalTrials":94,"cells":1989},"alvespimycin hydrochloride",{"EARLY_PHASE1":1990,"PHASE1":1992,"PHASE2":2004,"PHASE3":2006,"PHASE4":2008,"NA":2010},{"trials":1991,"activeCount":98},[],{"trials":1993,"activeCount":98},[1994],{"nctId":1995,"briefTitle":1996,"status":305,"phases":1997,"primaryCompletion":1998,"start":1999,"enrollment":2000,"conditions":2001,"interventions":2003},"NCT00248521","17-Dimethylaminoethylamino-17-Demethoxygeldanamycin (17-DMAG) in Treating Patients With Metastatic Solid Tumors or Tumors That Cannot Be Removed By Surgery",[86],"2007-01","2005-10",35,[2002],"Unspecified Adult Solid Tumor, Protocol Specific",[1988],{"trials":2005,"activeCount":98},[],{"trials":2007,"activeCount":98},[],{"trials":2009,"activeCount":98},[],{"trials":2011,"activeCount":98},[],{"intervention":2013,"totalTrials":259,"cells":2014},"Chemotherapy",{"EARLY_PHASE1":2015,"PHASE1":2017,"PHASE2":2019,"PHASE3":2021,"PHASE4":2034,"NA":2036},{"trials":2016,"activeCount":98},[],{"trials":2018,"activeCount":98},[],{"trials":2020,"activeCount":98},[],{"trials":2022,"activeCount":98},[2023],{"nctId":2024,"briefTitle":2025,"status":305,"phases":2026,"primaryCompletion":2027,"completion":2028,"start":2029,"enrollment":2030,"conditions":2031,"interventions":2033},"NCT01993979","A Phase III Randomised Trial of Peri-Operative Chemotherapy Versus sUrveillance in Upper Tract Urothelial Cancer (POUT)",[88],"2018-11-07","2022-05","2012-05",261,[2032],"Transitional Cell Carcinoma of Ureter",[2013],{"trials":2035,"activeCount":98},[],{"trials":2037,"activeCount":98},[2038],{"nctId":2039,"briefTitle":2040,"status":305,"phases":2041,"primaryCompletion":2042,"start":2043,"enrollment":2044,"conditions":2045,"interventions":2047},"NCT00253409","Combination Chemotherapy With or Without Surgery and Radiation Therapy in Treating Patients With Mesothelioma That Can Be Removed By Surgery",[90],"2011-06","2005-05",670,[2046],"Malignant Mesothelioma",[2048],"chemotherapy",{"intervention":1105,"totalTrials":259,"cells":2050},{"EARLY_PHASE1":2051,"PHASE1":2053,"PHASE2":2055,"PHASE3":2057,"PHASE4":2063,"NA":2065},{"trials":2052,"activeCount":98},[],{"trials":2054,"activeCount":98},[],{"trials":2056,"activeCount":98},[],{"trials":2058,"activeCount":98},[2059],{"nctId":1096,"briefTitle":1097,"status":265,"phases":2060,"completion":1099,"start":1100,"enrollment":1101,"conditions":2061,"interventions":2062},[88],[14],[1065,1050,1104,1068,1105,1106,1069,1070],{"trials":2064,"activeCount":98},[],{"trials":2066,"activeCount":98},[2067],{"nctId":2068,"briefTitle":2069,"status":265,"phases":2070,"completion":2071,"start":2072,"enrollment":2073,"conditions":2074,"interventions":2075},"NCT00031850","Raloxifene and Goserelin in Preventing Breast Cancer in Women With a Family History of Breast Cancer",[90],"2007-05","2000-03",150,[14],[1105,2076],"raloxifene",{"intervention":2078,"totalTrials":94,"cells":2079},"n\u002Fa - observational",{"EARLY_PHASE1":2080,"PHASE1":2082,"PHASE2":2084,"PHASE3":2086,"PHASE4":2088,"NA":2090},{"trials":2081,"activeCount":98},[],{"trials":2083,"activeCount":98},[],{"trials":2085,"activeCount":98},[],{"trials":2087,"activeCount":98},[],{"trials":2089,"activeCount":98},[],{"trials":2091,"activeCount":98},[2092],{"nctId":2093,"briefTitle":2094,"status":1642,"phases":2095,"primaryCompletion":2096,"completion":2096,"start":2097,"enrollment":24,"conditions":2098,"interventions":2100},"NCT02257775","Evolution of Resistance to Systemic Therapies in Patients With Breast Cancer",[],"2017-11-23","2015-05-11",[2099],"Metastatic Breast Cancer",[2078],{"intervention":2076,"totalTrials":94,"cells":2102},{"EARLY_PHASE1":2103,"PHASE1":2105,"PHASE2":2107,"PHASE3":2109,"PHASE4":2111,"NA":2113},{"trials":2104,"activeCount":98},[],{"trials":2106,"activeCount":98},[],{"trials":2108,"activeCount":98},[],{"trials":2110,"activeCount":98},[],{"trials":2112,"activeCount":98},[],{"trials":2114,"activeCount":98},[2115],{"nctId":2068,"briefTitle":2069,"status":265,"phases":2116,"completion":2071,"start":2072,"enrollment":2073,"conditions":2117,"interventions":2118},[90],[14],[1105,2076],{"intervention":2120,"totalTrials":94,"cells":2121},"therapeutic progesterone",{"EARLY_PHASE1":2122,"PHASE1":2124,"PHASE2":2126,"PHASE3":2128,"PHASE4":2130,"NA":2132},{"trials":2123,"activeCount":98},[],{"trials":2125,"activeCount":98},[],{"trials":2127,"activeCount":98},[],{"trials":2129,"activeCount":98},[],{"trials":2131,"activeCount":98},[],{"trials":2133,"activeCount":98},[2134],{"nctId":2135,"briefTitle":2136,"status":305,"phases":2137,"start":2138,"conditions":2139,"interventions":2143},"NCT00079248","Hormone Replacement Therapy in Relieving Menopausal Symptoms in Postmenopausal Women With Previous Stage I or Stage II Breast Cancer",[90],"2002-03",[14,2140,2141,2142],"Hot Flashes","Menopausal Symptoms","Osteoporosis",[2120,2144],"conjugated estrogens",{"intervention":2144,"totalTrials":94,"cells":2146},{"EARLY_PHASE1":2147,"PHASE1":2149,"PHASE2":2151,"PHASE3":2153,"PHASE4":2155,"NA":2157},{"trials":2148,"activeCount":98},[],{"trials":2150,"activeCount":98},[],{"trials":2152,"activeCount":98},[],{"trials":2154,"activeCount":98},[],{"trials":2156,"activeCount":98},[],{"trials":2158,"activeCount":98},[2159],{"nctId":2135,"briefTitle":2136,"status":305,"phases":2160,"start":2138,"conditions":2161,"interventions":2162},[90],[14,2140,2141,2142],[2120,2144]]